US OptionsDetailed Quotes
WFRD240517C100000
- 26.40
- 0.000.00%
15min DelayClose May 7 11:52 ET
0.00High0.00Low
0.00Open26.40Pre Close0 Volume0 Open Interest100.00Strike Price0.00Turnover1308.13%IV7.49%PremiumMay 17, 2024Expiry Date17.59Intrinsic Value100Multiplier-5DDays to Expiry8.81Time Value100Contract SizeAmericanOptions Type0.9801Delta0.0036Gamma4.45Leverage Ratio-12.1068Theta0.0001Rho4.37Eff Leverage0.0005Vega
Weatherford International Stock Discussion
Sign in to post a comment
2
$Weatherford International(WFRD.US$ another ah runner wow compared to today's earnings tomorrow is shaping up to be huge
1
$Weatherford International(WFRD.US$ waiting ur next climax
Weatherford International's rise in ROCE and decrease in capital employed suggest enhanced efficiency in generating returns. The substantial total return over the past three years signals investors' anticipation of more positive future performance.
Weatherford International's high P/S ratio isn't justified given its below-industry projected revenue growth. The company's current price levels and not so promising growth outlook warrant investor caution. Future disappointment is possible if P/S falls to match the growth outlook.
$Weatherford International(WFRD.US$ on the way rising
1
Market Summary 15/8/2023
August kicked off with a noticeable 5% dip in the QQQ. However, a respite was observed, likely due to the $ARK Innovation ETF(ARKK.US$ ETF's continuous downfall in the last nine sessions, leading to a significant 17% drop this month. Such sharp declines are expected after robust growth periods, but it's concerning when they coincide with a trend switch to net lows. Even with today's market uplift, there was a rise in net lows for the Nasdaq an...
August kicked off with a noticeable 5% dip in the QQQ. However, a respite was observed, likely due to the $ARK Innovation ETF(ARKK.US$ ETF's continuous downfall in the last nine sessions, leading to a significant 17% drop this month. Such sharp declines are expected after robust growth periods, but it's concerning when they coincide with a trend switch to net lows. Even with today's market uplift, there was a rise in net lows for the Nasdaq an...
20
2
Gainers:
• $DBV Technologies(DBVT.US$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics(ALDX.US$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $MediciNova(MNOV.US$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid(CURV.US$ +11% (In reaction to earnings/guidance)
• $Novavax(NVAX.US$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...
• $DBV Technologies(DBVT.US$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics(ALDX.US$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $MediciNova(MNOV.US$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid(CURV.US$ +11% (In reaction to earnings/guidance)
• $Novavax(NVAX.US$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...
23
Upgrades
• $Seres Therapeutics(MCRB.US$ : Jefferies Upgrades to Buy from Hold
• $Ferrari(RACE.US$ : Kepler Upgrades to Hold from Reduce
Downgrades
• $Dutch Bros(BROS.US$ : JPMorgan Downgrades to Neutral from Overweight - PT $40
• $Canopy Growth(CGC.US$ : BMO Capital Downgrades to Underperform from Market Perform - PT Cdn$2.50 (from Cdn$6)
• $Cazoo(CZOO.US$ : Citigroup Downgrades to Neutral from Buy - PT $1.50 (from $9)
• $Chart Industries(GTLS.US$ : Barcla...
• $Seres Therapeutics(MCRB.US$ : Jefferies Upgrades to Buy from Hold
• $Ferrari(RACE.US$ : Kepler Upgrades to Hold from Reduce
Downgrades
• $Dutch Bros(BROS.US$ : JPMorgan Downgrades to Neutral from Overweight - PT $40
• $Canopy Growth(CGC.US$ : BMO Capital Downgrades to Underperform from Market Perform - PT Cdn$2.50 (from Cdn$6)
• $Cazoo(CZOO.US$ : Citigroup Downgrades to Neutral from Buy - PT $1.50 (from $9)
• $Chart Industries(GTLS.US$ : Barcla...
13
2
No comment yet
Money Attractor : Change new blood, no worries
TheTruthOP Money Attractor: Mind sharing in details?